152 related articles for article (PubMed ID: 12948412)
21. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
22. Hypermethylation of calcitonin gene in adult acute leukemia at diagnosis and during complete remission.
Thomas X; Teillon MH; Belhabri A; Rimokh R; Fiere D; Magaud JP; Archimbaud E
Hematol Cell Ther; 1999 Feb; 41(1):19-26. PubMed ID: 10193642
[TBL] [Abstract][Full Text] [Related]
23. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
24. [Expression of bcl-2 gene in the evolution of chronic myelogenous leukemia to blast crisis and its implication].
Sui X; Su L; Chu J
Zhonghua Xue Ye Xue Za Zhi; 1999 Jan; 20(1):27-9. PubMed ID: 11498840
[TBL] [Abstract][Full Text] [Related]
25. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
Agrawal S; Unterberg M; Koschmieder S; zur Stadt U; Brunnberg U; Verbeek W; Büchner T; Berdel WE; Serve H; Müller-Tidow C
Cancer Res; 2007 Feb; 67(3):1370-7. PubMed ID: 17283175
[TBL] [Abstract][Full Text] [Related]
26. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M
J Clin Oncol; 2005 Jun; 23(18):4100-9. PubMed ID: 15867198
[TBL] [Abstract][Full Text] [Related]
27. Hypermethylation of the calcitonin gene in the myelodysplastic syndromes.
Ihalainen J; Pakkala S; Savolainen ER; Jansson SE; Palotie A
Leukemia; 1993 Feb; 7(2):263-7. PubMed ID: 8426480
[TBL] [Abstract][Full Text] [Related]
28. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
[TBL] [Abstract][Full Text] [Related]
29. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
30. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
[TBL] [Abstract][Full Text] [Related]
31. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias.
Chim CS; Wong AS; Kwong YL
Ann Hematol; 2003 Dec; 82(12):738-42. PubMed ID: 14513284
[TBL] [Abstract][Full Text] [Related]
34. Lipid peroxidation in leukaemia.
Ghalaut VS; Ghalaut PS; Singh S
J Assoc Physicians India; 1999 Apr; 47(4):403-5. PubMed ID: 10778525
[TBL] [Abstract][Full Text] [Related]
35. inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases.
Merzianu M; Medeiros LJ; Cortes J; Yin C; Lin P; Jones D; Glassman A; Kantarjian H; Huh Y
Am J Clin Pathol; 2005 Nov; 124(5):807-14. PubMed ID: 16203287
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic regulation of PRAME gene in chronic myeloid leukemia.
Roman-Gomez J; Jimenez-Velasco A; Agirre X; Castillejo JA; Navarro G; Jose-Eneriz ES; Garate L; Cordeu L; Cervantes F; Prosper F; Heiniger A; Torres A
Leuk Res; 2007 Nov; 31(11):1521-8. PubMed ID: 17382387
[TBL] [Abstract][Full Text] [Related]
37. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.
Qian J; Wang YL; Lin J; Yao DM; Xu WR; Wu CY
Eur J Haematol; 2009 Feb; 82(2):119-23. PubMed ID: 19018866
[TBL] [Abstract][Full Text] [Related]
38. [Abnormalities of chromosome 17 in myeloid malignancies with complex chromosomal abnormalities].
Zhu Y; Xu W; Liu Q; Pan J; Qiu H; Wang R; Qiao C; Jiang Y; Zhang S; Fan L; Zhang J; Shen Y; Xue Y; Li J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct; 25(5):579-82. PubMed ID: 18841577
[TBL] [Abstract][Full Text] [Related]
39. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse.
Sperr WR; Mitterbauer M; Mitterbauer G; Kundi M; Jäger U; Lechner K; Valent P
Clin Cancer Res; 2005 Sep; 11(18):6536-43. PubMed ID: 16166430
[TBL] [Abstract][Full Text] [Related]
40. Myeloperoxidase cytochemical negativity: an unexpected but intrinsic property of blasts of all phases of chronic myeloid leukemia.
Anand M; Ghara N; Kumar R; Singh S; Sengar M; Panikar N; Raina V; Sharma A
Ann Hematol; 2005 Nov; 84(12):767-70. PubMed ID: 15990995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
